Tirzepatide common uses, half-life, side effects and more

Tirzepatide is a once weekly injectable drug for type 2 diabetes, weight management, and obstructive sleep apnea. It acts on two of the gut hormone systems that control blood sugar and appetite. It is FDA approved and sold by prescription under two brand names. Mounjaro treats type 2 diabetes in adults and in children age 10 and older. Zepbound is approved for adults to manage weight in obesity or overweight with a weight related condition. It also treats moderate to severe obstructive sleep apnea in adults with obesity. The two brands are the same molecule but are not interchangeable across their approved uses. People also buy tirzepatide outside the pharmacy as research labeled powder or compounded vials. These copies are not FDA approved and carry no verified strength. They should not be treated as equal to the approved pens and vials.

• Blood sugar control in adults and children age 10 and older with type 2 diabetes
• Long term weight management in obesity or overweight with a related condition
• Moderate to severe obstructive sleep apnea in adults with obesity
• Reduced appetite and food cravings during weight loss
• Weight loss bought outside approved channels as research powder

Once weekly

Adults start at 2.5 mg under the skin once weekly for 4 weeks. This first dose builds tolerance and is not a maintenance dose. The dose then rises to 5 mg once weekly. It can increase further in 2.5 mg steps no more often than every 4 weeks to a maximum of 15 mg once weekly. Maintenance for type 2 diabetes and for weight management is 5 mg, 10 mg, or 15 mg once weekly. Maintenance for obstructive sleep apnea is 10 mg or 15 mg once weekly. Children age 10 and older with type 2 diabetes start the same way but stop at a maximum of 10 mg once weekly. Gray-market users reconstitute research powder from 10 mg, 30 mg, or 60 mg vials and mostly copy the same slow climb. Many stay in the 2.5 mg to 7.5 mg per week range rather than climbing to the ceiling. Some split the weekly amount into two or three smaller injections across the week.

• Take the weekly dose on any day of the week with or without food
• A missed weekly dose can be taken within 4 days of the scheduled day or otherwise skipped
• A 30 mg vial in 3 mL of bacteriostatic water makes 10 mg per mL and puts a 2.5 mg dose at 25 units on a U-100 insulin syringe

About 5 days in humans. This long half-life supports once weekly dosing.

Approved pens and vials are stored in the refrigerator between 2 and 8 degrees Celsius. Single dose pens and single dose vials can sit at room temperature up to 30 degrees for 21 days before they are discarded. Multi-dose vials and single-patient pens allow 30 days at room temperature instead. Do not freeze tirzepatide and keep it in the original carton away from light.

• Nausea, diarrhea, vomiting, constipation, and abdominal pain are the most common effects and cluster during dose increases
• Decreased appetite and early fullness are expected and can feel excessive during the climb
• Injection site redness, itching, or bruising can occur
• Fatigue is common during dose increases and periods of low food intake
• Hair shedding can happen during rapid weight loss
• Pancreatitis, gallbladder disease, severe allergic reactions, or kidney injury from dehydration are uncommon but serious

Tirzepatide is a single 39 amino acid peptide that activates the GIP receptor and the GLP-1 receptor at the same time. Both are receptors for natural gut hormones the body releases after eating. It raises insulin only when blood sugar is high and lowers glucagon under the same condition. It slows stomach emptying and reduces appetite through signals to brain centers that control hunger. The stomach slowing is strongest after the first dose and fades with continued use. A long C20 fatty acid chain binds it to albumin and keeps it working for about 5 days. Adding GIP activity is thought to give extra weight and blood sugar benefit beyond GLP-1 alone. How much each receptor contributes in people is still debated.

The approved uses rest on a large base of randomized human trials. The SURPASS program tested it in type 2 diabetes against placebo and active drugs and lowered A1c by about 2 percentage points. SURMOUNT-1 gave adults with obesity and no diabetes 72 weeks of treatment and produced mean weight loss of 15.0 percent at 5 mg, 19.5 percent at 10 mg, and 20.9 percent at 15 mg against 3.1 percent on placebo. A 176 week extension held the weight off and cut progression to type 2 diabetes. SURMOUNT-OSA lowered sleep apnea severity over 52 weeks in people using and not using a breathing machine. The cardiovascular outcome trial SURPASS-CVOT matched but did not beat an older GLP-1 drug for heart events. The label carries no heart risk claim. Evidence for compounded, counterfeit, or research labeled tirzepatide is not the same as evidence for the approved products.

• Tirzepatide carries a boxed warning for thyroid C-cell tumors seen in rats and must not be used by anyone with a personal or family history of medullary thyroid cancer or MEN 2
• Severe or lasting abdominal pain can signal pancreatitis or gallbladder disease and needs prompt medical care
• Heavy vomiting or diarrhea can cause dehydration and acute kidney injury
• Combining it with insulin or a sulfonylurea raises the risk of low blood sugar and may need those doses lowered
• Tirzepatide is not advised in pregnancy and can weaken oral birth control for 4 weeks after starting or raising the dose
• Slowed stomach emptying can leave food in the stomach before anesthesia and raise the risk of breathing it into the lungs